The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Top Four Biotech Trends of 2009

These may not all be consensus picks (and don’t miss the IVB’s year-end deal-centric fun) but I’m sticking with these four trends as the ones that have really shaped the year that was:

  1. Follow-on Biologics. Call them what you want (we like “biosimilars”, but we’re internationalist like that), there’s no denying that biosimilars were a major force in the industry and in politics this year.  Some in the press are calling the 12-year exclusivity period a done deal, but I say don’t count your chickens ’til the fat lady sings.
  2. Comparative Effectiveness and Personalized Medicine (not a two-fer, a trend of convergence). How much of comparative effectiveness variation will turn out to be an artifact of genetic sub-populations (each with binary responses to the drugs in question)?  Nobody knows, but as money pours into both fields, the truth will set us (and drug pricing) free.
  3. Shifting IP Constituencies. What do you get when you cross generics-hungry pharma companies with innovation-hungry Asian countries?  A whole new world of collaboration that will ultimately change the face of TRIPS and pharma R&D.
  4. Electronic Medical Records. Not really biotech (if you want to be picky), but it will have a massive impact on the way physicians, patients and payors interact with each other and with drug companies over the coming years.  Plus, with billions allocated to electronic medical records in Canada and the U.S., the pace of innovation and implementation really took off.

Bookmark and Share

About these ads

5 responses to “Top Four Biotech Trends of 2009

  1. Pingback: Biotech Trends of 2009: Three Biggest Losers « The Cross-Border Biotech Blog

  2. Pingback: Top 10 Cross-Border Biotech Blog Posts of 2009 « The Cross-Border Biotech Blog

  3. Pingback: Monday Biotech Deal Review: January 4, 2010 « The Cross-Border Biotech Blog

  4. Pingback: Biotech Trends Update — Personalized Medicine: The Case for Diagnostics Focuses on Cost and Effectiveness « The Cross-Border Biotech Blog

  5. Pingback: Personalized Medicine: The case for diagnostics focuses on cost and effectiveness « The RIC Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 130 other followers